Immunotherapy has transformed the treatment of solid organ cancers, rapidly becoming a first line therapy with transformative durable response. While immunotherapies have favorable toxicity profiles compared to traditional chemotherapies, immunotherapy is associated with the development of immune-related adverse events (irAEs), an autoimmune condition incited by activation of the immune system.

20% to 60% of patients receiving immune checkpoint inhibitors (ICIs) will experience severe irAEs that can limit therapeutic continuation of treatment. Severe iRAEs that occur in major organs can be life-threatening, and these adverse events have profound influence on the overall outcomes associated with checkpoint inhibitor drugs.

There is a pressing need to identify reliable biomarkers that further elucidate how immunotherapies modify existing immune responses to disease, predict toxicities, and help to guide the treatment and management of at-risk patients.

Download this case study to learn how Sapient discovered a robust, specific circulating biomarker that identifies individuals who are at risk for severe autoimmune events in the setting of ICI.